Key Insights

Highlights

Success Rate

100% trial completion (above average)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 40/100

Termination Rate

0.0%

0 terminated out of 19 trials

Success Rate

100.0%

+13.5% vs benchmark

Late-Stage Pipeline

11%

2 trials in Phase 3/4

Results Transparency

12%

2 of 17 completed with results

Key Signals

2 with results100% success

Data Visualizations

Phase Distribution

18Total
Not Applicable (6)
P 1 (5)
P 2 (5)
P 3 (2)

Trial Status

Completed17
Unknown1
Active Not Recruiting1

Trial Success Rate

100.0%

Benchmark: 86.5%

Based on 17 completed trials

Clinical Trials (19)

Showing 19 of 19 trials
NCT07254871Phase 2Active Not RecruitingPrimary

Study of DM-101PX in Adults With Birch Pollen Allergy

NCT05668390Phase 3Completed

Safety and Efficacy of STALORAL® Birch 300 IR in a Paediatric Population With Birch Pollen-induced ARC w/o Asthma

NCT05346718Not ApplicableCompleted

Threshold Concentrations for Ragweed and Birch Pollen in Seasonal Allergic Rhinitis

NCT06803953Not ApplicableCompleted

Evaluation of an Adjusted Cutoff Value for S.P.A.T (Skin Prick Automated Test) Device in Allergic Subjects

NCT06037148Phase 1CompletedPrimary

Study to Evaluate Safety, Tolerability and Explorative Efficacy of DM-101PX in Birch Pollen Allergic Participants

NCT04912076Phase 1CompletedPrimary

S.C. Immunotherapy With BM41 in Patients With Allergic Rhino-conjunctivitis Caused by Birch Pollen

NCT04266028Phase 1CompletedPrimary

Study to Evaluate Safety and Tolerability of sc Immunotherapy With DM-101 in Adults With Birch Pollen Allergy

NCT04435678Not ApplicableCompletedPrimary

Diagnostic Accuracy of the MADx Multi Array Xplorer (MAX 45k) Automated Laboratory System and the MADx Allergy Explorer Version 2 (ALEX²) - IgE Multiplex Test for the Diagnosis of Pre-defined Groups of Specific High-priority Allergens

NCT03969849Phase 1Completed

Study to Assess the Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Effects of a Single Dose of REGN5713-5714-5715 in Healthy Adult Participants

NCT01449786Phase 2Completed

Sublingual Immunotherapy of Birch Pollen Associated Apple Allergy

NCT02143583CompletedPrimary

Follow-up of Study AN004T to Assess the Persistence of AllerT Efficacy During the 2nd to 4th Season After Treatment

NCT02146300Not ApplicableUnknownPrimary

Effect of the Nasal Provocation on the Breathing Style

NCT02074930Not ApplicableCompletedPrimary

Comparison of the Influence of Different Skin Conditions on the Allergic Skin Reactivity to Epicutanous Allergen Exposure

NCT01675791Phase 2CompletedPrimary

A Dose-response Evaluation of ALK (the Sponsor) Tree Allergy Immunotherapy Tablet

NCT00309062Phase 3CompletedPrimary

Safety and Efficacy of Recombinant Birch Pollen Allergen in the Treatment of Allergic Rhinoconjunctivitis

NCT00266526Phase 2CompletedPrimary

Specific Immunotherapy With Recombinant Birch Pollen Allergen rBet v1-FV

NCT01628484Phase 1CompletedPrimary

Physiological Study to Determine the Allergic Skin Activity After Different Skin Preparation

NCT00932607Phase 2Completed

SUBLIVAC® Birch PROBE Study

NCT01137357Not ApplicableCompleted

Probiotics for Reduction Of Markers In Subjects With Allergy

Showing all 19 trials

Research Network

Activity Timeline